US Stock MarketDetailed Quotes
INTS Intensity Therapeutics
- 5.090
- +0.070+1.39%
Close Jul 12 16:00 ET
69.79MMarket Cap-4614P/E (TTM)
5.090High4.960Low3.48KVolume4.960Open5.020Pre Close17.55KTurnover0.06%Turnover RatioLossP/E (Static)13.71MShares11.44052wk High7.18P/B31.61MFloat Cap2.01052wk Low--Dividend TTM6.21MShs Float11.440Historical High--Div YieldTTM2.59%Amplitude2.010Historical Low5.037Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Intensity Therapeutics Stock Forum
Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma
Intensity Therapeutics (Nasdaq: INTS) has announced the dosing of the first U.S. patient in its global Phase 3 study (INVINCIBLE-3) for metastatic soft tissue sarcoma using its lead product candidate, INT230-6, as a monotherapy. This trial will compare INT230-6 against standard-of-care chemotherapy in second and ...
Intensity Therapeutics Signs Collaboration Agreement With The Swiss Group For Clinical Cancer Research SAKK To Conduct Phase 2 Breast Cancer Trial In Europe For INT230-6
NEWS
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate
Positive
The collaboration agreement between Intensity Therapeutics, Inc. and SAKK for the Phase 2 clinical trial demonstrates the company's commitment to advancing its lead drug candidate, INT230-6.
INT230-6 has s...
$Leap Therapeutics(LPTX.US)$ Phase 2
$Vera Therapeutics(VERA.US)$ Phase 2b
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$Akero Therapeutics(AKRO.US)$ Phase 2b
$Spruce Biosciences(SPRB.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$Annexon(ANNX.US)$ Phase 2a
$Roivant Sciences(ROIV.US)$...
Benzinga· 3 mins ago
🔥 biotech company focused on interventions for inflammatory and oncologic diseases
🔥 Strong technical setup: 4-hour chart demonstrating bullish descending wedge
🔥 Strong pipeline with recently published positive Phase 1 data for TH104, its lead candidate for chronic pruritus in PBC
🔥 Market cap $1m, highly undervalued, should easily be a minimum $6m market cap
🔥Oversold, RSI 25
🔥 Recently closed offering (priced at $1.00/sh),...
hooo
No comment yet